Blaze Bioscience Announces Trial in Progress Presentation at ASCO 2016 Annual Meeting

On May 31, 2016 Blaze Bioscience, Inc., the Tumor Paint Company, a biotechnology company focused on guided cancer therapy, reported that the company’s Senior Vice President of Development, Dennis Miller, Ph.D., will present at the American Society of Surgical Oncology (ASCO) (Free ASCO Whitepaper) 2016 Annual Meeting, taking place in Chicago, IL on June 3-7, 2016 (Press release, Blaze Bioscience, MAY 31, 2016, View Source [SID:1234512904]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation, titled "Phase 1 Dose Escalation and Expansion Safety Study of BLZ-100 in Pediatric Subjects with Primary Central Nervous System Tumors," will highlight the company’s first study in the pediatric population.

Details of the poster presentation are as follows:
Trials in Progress Presentation – Pediatric Oncology Session
Date: Monday, June 6, 2016
Time: 8:00 AM – 11:30 AM CDT
Location: Hall A Poster
Number: 274b
Abstract Number: TPS10584

About BLZ-100
BLZ-100 is the first product candidate from Blaze’s Tumor Paint platform and consists of an Optide (optimized peptide) and a fluorescent dye, which emits light in the near-infrared range. Tumor Paint products are designed to provide real-time, high-resolution intraoperative visualization of cancer cells, potentially enabling more precise, complete resection of cancer throughout surgery. Preclinical utility of Tumor Paint technology has been demonstrated in a wide range of cancer types. BLZ-100 is an investigational agent currently in multiple Phase 1 proof-of-concept clinical studies to evaluate the safety and imaging characteristics of BLZ-100 in solid tumors, including brain, breast, lung, prostate, and colorectal cancer. More details about on-going trials are available at www.blazebioscience.com or www.clinicaltrials.gov.